C the Signs

London, United Kingdom  All United Kingdom companies → — Founded 2017
Clinical AI Platform Specialty-Focused AI
Family Medicine Internal Medicine Oncology
Clinical Decision Support & Reference Oncology AI
Series A/Early-Stage VC (recently secured Series B funding) — $21M (as of early 2025)
Website Claim this company

Products

C the Signs
C the Signs Ltd.
Clinical Decision Support & Reference
C the Signs uses artificial intelligence (AI) to identify patients at risk of cancer at the earliest, most curable stage. The company aims to change the course of cancer, fueled by humanity, powered by science, and grounded in the belief that everyone, everywhere, deserves the chance to survive.
Contact for pricing

See all 1 product →

About C the Signs

C the Signs is an AI-powered clinical platform designed to revolutionize early cancer detection. Founded by NHS doctors, the company’s mission is to make early cancer detection a standard for all patients, not a privilege. The platform integrates seamlessly with electronic health records (EHRs) and utilizes artificial intelligence to analyze a wide array of patient data points, including clinical signs, symptoms, risk factors, lifestyle, family history, medical history, drug history, comorbidities, and past test results. This comprehensive analysis allows the system to identify patients at risk of over 100 cancer types, often before a clinician might suspect it, and recommend the most appropriate diagnostic tests or referrals in under 60 seconds.

By proactively identifying high-risk individuals, C the Signs aims to shift healthcare from a reactive to a predictive model, significantly increasing the chances of survival by detecting cancers at their earliest and most curable stages (Stage 1 or 2). The platform has demonstrated impressive results within the UK’s National Health Service (NHS), identifying breast cancer cases years earlier than standard pathways and improving early-stage ovarian cancer diagnoses. Beyond clinical decision support, C the Signs also offers population risk stratification, automated tracking and safety-netting of patients, and real-time dashboards with cancer performance data, contributing to reduced diagnostic delays, improved patient outcomes, and a more equitable and cost-effective cancer care pathway.

What Physicians Need to Know

Specialization
C the Signs specializes in AI-powered clinical decision support for early cancer detection. Their platform helps healthcare professionals identify patients at risk of cancer earlier, faster, and more accurately.
Key Differentiators
C the Signs differentiates itself through its high sensitivity (99% for identifying patients with cancer), high negative predictive value (99% for safely ruling out risk), and 94% accuracy in predicting tumor origin. It analyzes a wide range of personal and environmental data points beyond basic risk factors like age and gender, including demographic, lifestyle, family history, medical history, drug history, comorbidities, and past test results. The platform also offers both active risk assessment during consultations and passive risk assessment by screening electronic medical records. It's built by doctors for doctors, ensuring real-time clinical support seamlessly integrated into existing workflows.
Technology Stack
The company utilizes a microservice cloud-based architecture for resilience and scalability. Early infrastructure included AWS services like EC2, S3, and Elastic Cloud. The platform is designed for interoperability and integrates with electronic health record (EHR) systems.
Physician Tip

For physicians, C the Signs offers a tool to make faster, more confident decisions while maintaining clinical autonomy. It provides instant, tailored guidance on next steps, from urgent referrals to diagnostic tests, in under 30-60 seconds. The platform helps identify rare, complex, or vague cancer presentations and recommends personalized investigations or referrals based on national and local guidelines, drawing on over 1,000 validated signs, symptoms, and risk factors. It can reduce unnecessary screenings by ruling out low-risk patients, thereby easing the burden on primary care and healthcare resources. The system also includes real-time dashboards for tracking suspected and confirmed cancer patients, automating safety-netting, and providing performance data. This can lead to a significant increase in cancer detection rates, as demonstrated by a 12.3% increase in one study, without requiring additional staff time.

C the Signs is built with interoperability at its core and seamlessly integrates into electronic health record systems. Specifically, it integrates with NHS electronic medical record systems such as EMIS, SystmOne, and Vision, covering over 97% of primary care EHR systems in the UK. It is FHIR/HL7 compliant. The platform works within existing electronic health records, aiming for no extra clicks and no disruption to workflow.

Products by C the Signs

1 product in the directory

C the Signs
C the Signs Ltd.
Clinical Decision Support & Reference
C the Signs uses artificial intelligence (AI) to identify patients at risk of cancer at the earliest, most curable stage. The company aims to change the course of cancer, fueled by humanity, powered by science, and grounded in the belief that everyone, everywhere, deserves the chance to survive.
Contact for pricing

What the Web Says

C the Signs is an AI-powered medical device designed to help General Practitioners (GPs) detect and refer patients at risk of cancer earlier. The platform analyzes over 1000 validated data points to identify cancer at its earliest, most curable stage, aiming to reduce diagnosis time and improve survival rates. It has shown success in the UK's National Health Service (NHS), identifying breast cancer cases earlier and improving early-stage ovarian cancer diagnosis. The company is expanding to the United States.

Overall: Positive

Strengths

  • AI-powered early cancer detection with high sensitivity (99%).
  • Reduces time to diagnosis.
  • Improves early-stage diagnosis for various cancers (e.g., breast, ovarian).
  • Multi-platform decision support tool for doctors.
  • Covers the whole spectrum of cancer, from childhood to old age.
  • Regulated by the Medicines Healthcare and products Regulatory Agency (MHRA).

Limitations

  • Limited public reviews available on platforms like G2, Glassdoor, and Capterra.
  • No specific product or employer reviews found on Reddit.

Based on reviews from: C the Signs (cthesigns.com), Reddit, App Store - Apple, Apps on Google Play, PitchBook, C the Signs Raises $8M to Expand AI-Powered Cancer Detection to the U.S. -

Last updated: 2026-06-19

Videos

News, demos, and interviews about C the Signs.

Loading videos...

Videos load interactively. If none appear, search YouTube for C the Signs →

View all on YouTube

Press & Coverage

Newsweek
New cancer risk tool that flags patients early seeks FDA approval - Newsweek
C the Signs, an AI-powered cancer detection tool, is currently under review by the FDA for potential approval in the U.S. The company aims to launch the tool next year, which analyzes medical records to identify cancer risk without additional imaging.
2026-06
The SaaS News
AI Cancer Detection Startup C the Signs Secures $8M to Revolutionise Early Diagnosis
C the Signs, a London-based AI-powered cancer detection platform, has secured $8 million in funding from Khosla Ventures to accelerate its expansion into the U.S. market. The platform identifies patients at risk of cancer at its earliest and most treatable stage by analyzing electronic health records.
2025-01
Business Wire
C the Signs Announces Investment From Khosla Ventures to Advance AI-Powered Early Cancer Detection - Business Wire
C the Signs announced an $8 million investment from Khosla Ventures to expand its AI-based platform for early cancer detection from the U.K. to the U.S. The platform has shown success in the NHS, identifying breast, ovarian, and colorectal cancers earlier than traditional methods.
2025-01
PR Newswire
Real-world study across 1,000+ NHS GP practices shows AI-led triage detected 20% more patients with cancer while reducing unnecessary urgent referrals by over 61,000 patients. - PR Newswire
New research published in Cancer Research and presented at the AACR Annual Meeting 2025 indicates that C the Signs' AI-led cancer triage platform significantly improved early cancer detection rates and reduced pressure on the NHS. The study, involving over 1,000 GP practices, found a 20% improvement in cancer conversion rates and avoided over 61,000 unnecessary urgent cancer referrals.
2025-04
Journal of Clinical Oncology
Leveraging electronic medical records for early lung cancer diagnosis: An evaluation of the C the Signs AI cancer prediction platform using the Mayo data platform. - ASCO Publications
A study published in the Journal of Clinical Oncology highlights the potential of C the Signs' AI platform in enhancing early lung cancer detection by leveraging EMR data. The platform achieved a sensitivity of 91.5% and identified 26.6% of cases up to five years earlier than traditional diagnoses.
2025-05
JCO Oncology Practice
Evaluating the impact of an AI cancer prediction platform on early interception of the five deadliest cancers: A retrospective study using real-world data. | JCO Oncology Practice - ASCO Publications
This retrospective study, utilizing data from the Mayo Data Platform, demonstrated that the C the Signs AI cancer prediction platform significantly improved early cancer interception for the five deadliest cancers. The platform identified 26.2% of cancer cases earlier than physician diagnosis, with the highest impact seen in prostate cancer.
2025-10
C the Signs Newsroom
C the Signs and NHS Suffolk & North East Essex ICB shortlisted for HSJ Partnership Award.
C the Signs' partnership with NHS Suffolk & North East Essex Integrated Care Board (ICB) has been shortlisted for Best Technology Partnership with the NHS at the 2026 HSJ Partnership Awards. This recognition is for their collaborative program in primary care that improved early cancer detection.
2026-01
C the Signs Newsroom
Mayo Clinic Magazine Highlights C the Signs' Impact on Early Cancer Diagnosis
Mayo Clinic Magazine featured C the Signs, highlighting its journey, scientific breakthroughs, and mission to transform cancer diagnosis globally. Retrospective analysis showed the platform identified cancers up to five years earlier in 26% of patients across five high-mortality cancer types.
2025-07

Frequently Asked Questions

C the Signs offers an AI Cancer Prediction Platform designed to improve earlier and faster cancer detection. It's a cloud-based software that integrates with electronic medical record systems (EMIS, SystmOne, Vision) to identify patients at risk of cancer in under 30 seconds. The platform provides real-time decision support, automated tracking and safety-netting for patients with suspected or diagnosed cancer, population risk stratification, and a real-time cancer dashboard with performance data. It also facilitates real-time patient communication and triages patients to the correct clinical pathway.
C the Signs is committed to protecting patient privacy and personal data. Their platform is UKCA marked and registered with the Medicines and Healthcare products Regulatory Agency as a class one medical device. They are also working with the FDA to determine the best regulatory pathway for the U.S. market. The company's privacy policy details what data they collect, how it's used, and user rights, emphasizing transparency in data use. They maintain encryption and protection of data, including NHS numbers, and facilitate audit and log tracing of user actions. While the search results mention general data protection regulations like GDPR, specific details on how C the Signs adheres to each aspect of HIPAA or GDPR beyond general privacy commitments are not explicitly provided.
C the Signs' pricing is listed at u00a30.20 to u00a30.33 per unit per year, with a free trial available. While a specific breakdown of different tiers or subscription options for various healthcare organizations isn't detailed, the pricing is presented on a per-unit annual basis.
C the Signs offers support for technical issues and user queries via email and a help desk phone number. They are also noted for being very good at providing education and are available to offer training to users. The company emphasizes embedding their platform into everyday clinical workflows and working closely with GP practices and cancer alliances to ensure strong adoption and clinical confidence.
C the Signs has a partnership with the Mayo Clinic, where their AI model was used to analyze patient records for colorectal cancer detection. They have also been selected for the White House-backed CancerX Accelerator program, collaborating with organizations like AstraZeneca, Intel, Dell Technologies, and AWS. Additionally, they have received funding from Khosla Ventures, known for backing AI-driven healthcare technologies.
C the Signs is a venture-backed company that recently secured $8 million in Series B funding from Khosla Ventures, bringing their total fundraising to $15 million. This funding is intended to expand their technology and capabilities, and to facilitate their entry into the U.S. market, where they are building a team and working with the FDA. They aim to expand their AI-powered early cancer detection platform to revolutionize cancer care in the United States.
C the Signs' AI platform has demonstrated high accuracy and effectiveness. It has a reported sensitivity of 99%, a negative predictive value (NPV) of 99%, and a tumor site accuracy of 94%. Studies have shown it can identify patients at risk of cancer earlier than traditional diagnoses, with some cancers flagged up to five years before conventional methods. For example, it identified 20.7% of breast cancer cases up to five years earlier and improved early detection of ovarian cancer by 53.3%. Research with the Mayo Clinic showed a sensitivity of 93.8% for colorectal cancer, comparable to a colonoscopy. The platform has been validated in real-world studies and has helped detect over 70,000 patients with cancer.

Investors

Who's funded C the Signs.

MMC Ventures
VC AI T3
London, United Kingdom
$1M-$5M
MMC Ventures is a London-based research-led venture firm that has built its reputation on understanding applied AI before it was fashionable. The…
AI/ML in Healthcare Health IT / Healthcare Software

Related Companies

CAIMed (Niedersächsisches Zentrum für KI und Kausale Methoden in der Medizin)
Hannover, Germany (Lower Saxony region)

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm
Berkeley, United States and London, United Kingdom. European office in Barcelona, Spain and Gothenburg, Sweden.

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA
London, UK

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Fraunhofer-Gesellschaft (Fraunhofer AICOS) / PALMX APPS LTD / Skin Analytics
London, United Kingdom

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]
MedTalk AI
Canberra, ACT, Australia

MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]
allergoSMART
Boizenburg / Elbe, Germany

allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]
Suggest an Edit →
AI Tool Finder
AI-powered search. Results may not be comprehensive.